Mn Services Vermogensbeheer B.V. boosted its position in shares of Biogen Inc. (NASDAQ:BIIB) by 518.1% during the second quarter, according to its most recent filing with the SEC. The fund owned 35,865 shares of the biotechnology company’s stock after buying an additional 30,063 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Biogen were worth $9,732,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BIIB. Dillon & Associates Inc. boosted its position in Biogen by 0.3% in the first quarter. Dillon & Associates Inc. now owns 1,785 shares of the biotechnology company’s stock worth $487,000 after buying an additional 5 shares in the last quarter. Beacon Trust Co. boosted its position in Biogen by 0.5% in the first quarter. Beacon Trust Co. now owns 1,135 shares of the biotechnology company’s stock worth $328,000 after buying an additional 6 shares in the last quarter. Guardian Life Insurance Co. of America boosted its position in Biogen by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 839 shares of the biotechnology company’s stock worth $229,000 after buying an additional 6 shares in the last quarter. Trust Co. of Vermont boosted its position in Biogen by 0.3% in the first quarter. Trust Co. of Vermont now owns 2,412 shares of the biotechnology company’s stock worth $660,000 after buying an additional 7 shares in the last quarter. Finally, Buckingham Capital Management Inc. boosted its position in Biogen by 0.3% in the first quarter. Buckingham Capital Management Inc. now owns 2,452 shares of the biotechnology company’s stock worth $670,000 after buying an additional 8 shares in the last quarter. 88.38% of the stock is currently owned by institutional investors and hedge funds.

Biogen Inc. (NASDAQ:BIIB) traded down 0.14% during trading on Friday, hitting $284.01. 383,769 shares of the company were exchanged. The stock’s 50-day moving average is $282.82 and its 200-day moving average is $274.33. Biogen Inc. has a 12 month low of $244.28 and a 12 month high of $304.23. The company has a market capitalization of $60.05 billion, a price-to-earnings ratio of 18.64 and a beta of 0.79.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Tuesday, July 25th. The biotechnology company reported $5.04 earnings per share for the quarter, beating analysts’ consensus estimates of $4.36 by $0.68. Biogen had a net margin of 28.10% and a return on equity of 37.42%. The business had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $2.81 billion. During the same period last year, the business earned $5.21 earnings per share. The business’s revenue for the quarter was up 6.4% on a year-over-year basis. Equities research analysts anticipate that Biogen Inc. will post $21.44 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Biogen Inc. (BIIB) Shares Bought by Mn Services Vermogensbeheer B.V.” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/08/18/biogen-inc-biib-shares-bought-by-mn-services-vermogensbeheer-b-v.html.

Several research firms have issued reports on BIIB. Morgan Stanley restated an “equal weight” rating and set a $307.00 price target on shares of Biogen in a research report on Wednesday, June 14th. UBS AG upgraded shares of Biogen from a “sell” rating to a “neutral” rating and increased their target price for the stock from $262.00 to $270.00 in a report on Monday, June 19th. Leerink Swann reiterated a “market perform” rating and set a $338.00 target price (up from $304.00) on shares of Biogen in a report on Wednesday, July 26th. Vetr lowered shares of Biogen from a “buy” rating to a “hold” rating and set a $298.30 target price for the company. in a report on Wednesday, July 26th. Finally, Goldman Sachs Group, Inc. (The) upgraded shares of Biogen from a “buy” rating to a “conviction-buy” rating and set a $338.00 target price for the company in a report on Wednesday. Eleven investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $328.81.

In other news, EVP Susan H. Alexander sold 7,758 shares of the firm’s stock in a transaction that occurred on Wednesday, July 19th. The shares were sold at an average price of $285.00, for a total value of $2,211,030.00. Following the completion of the transaction, the executive vice president now owns 27,232 shares of the company’s stock, valued at $7,761,120. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Brian S. Posner sold 1,084 shares of the firm’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $256.31, for a total transaction of $277,840.04. Following the completion of the transaction, the director now directly owns 6,330 shares of the company’s stock, valued at approximately $1,622,442.30. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,816 shares of company stock valued at $3,931,380. Company insiders own 0.32% of the company’s stock.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Stock Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related stocks with our FREE daily email newsletter.